BRAF and melanoma: In another study of 93 patients with BRAF-mutated melanoma who received BRAF inhibitors (vemurafenib or dabrafenib) before or after ipilimumab, longer OS was found in the cohort of patients receiving ipilimumab prior to BRAF inhibitor therapy (14.5 vs. 9.9 months, P = 0.04) [49].